Psychostimulants for cancer-related cognitive impairment in adult cancer survivors: a systematic review and meta-analysis
Cognitive impairment is recognized as a common symptom experienced by cancer survivors which impacts on quality of life (QoL) and day-to-day activities. One of the treatment options is the use of psychostimulants but the evidence supporting its use remains unclear.
To identify the level of evidence of psychostimulants’ effect on the management of cognitive impairment in adult cancer survivors.
Electronic databases (MEDLINE, EMBASE, CENTRAL, CINAHL) and reference lists of relevant reviews were searched from inception to December 2017, with no language restrictions applied. Randomized controlled trials (RCTs), evaluating the effect of psychostimulants on cognitive impairment among cancer patients with no primary or secondary brain tumor or brain radiation, were included. The primary outcome was cognitive function changes, whereas secondary outcomes were adverse events (AEs) and QoL.
Six RCTs were included: three studies investigating methylphenidate and three modafinil, with a total of 244 and 146 patients, respectively. Due to important differences in methodologies between studies, a meta-analysis was assumed inappropriate for the primary outcome. A narrative synthesis was performed. One study using methylphenidate and two using modafinil demonstrated improvements in some cognitive functions as measured by objective cognitive assessment tests. Psychostimulants did not improve QoL and were not associated with more AEs.
To date, limited evidence is available to estimate the usefulness (or lack) of psychostimulants on cognitive function in this population.
KeywordsCancer Cognitive impairment Psychostimulants Survivorship
Compliance with ethical standards
Conflict of interest
The corresponding author (NM) received a scholarship from Université Laval. This study was not done on primary data. Original data can be obtained from the primary authors of articles part of this review.
- 1.Canadian Cancer Statistics. http://www.cancer.ca [Internet]. 2016. Accessed 17 June 2019.
- 3.Jansen CE, Cancer Basics J, Eggert I (eds) (2010) Pittsburgh, PA: oncology nursing. society.Google Scholar
- 21.Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton Cet al Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol 2015;33(34):4085–4092Google Scholar
- 22.Bernstein LJ, Pond GR, Gan HK, Tirona K, Chan KK, Hope A, Kim J, Chen EX, Siu LL, Razak ARA (2018) Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort. Head Neck 40(9):2029–2042CrossRefPubMedGoogle Scholar
- 25.Mayo S, Messner HA, Rourke SB, Howell D, Victor JC, Kuruvilla J, Lipton JH, Gupta V, Kim DD, Piescic C, Breen D, Lambie A, Loach D, Michelis FV, Alam N, Uhm J, McGillis L, Metcalfe K (2016) Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation. Bone Marrow Transplant 51(6):841–847CrossRefPubMedGoogle Scholar
- 26.McDowell LJ, Ringash J, Xu W, Chan B, Lu L, Waldron J, Rock K, So N, Huang SH, Giuliani M, Hope A, O’Sullivan B, Bratman SV, Cho J, Kim J, Jang R, Bayley A, Bernstein LJ (2019) A cross sectional study in cognitive and neurobehavioral impairment in long-term nasopharyngeal cancer survivors treated with intensity-modulated radiotherapy. Radiother Oncol 131:179–185CrossRefPubMedGoogle Scholar
- 30.Janelsins MC, Heckler CE, Peppone LJ, Kamen C, Mustian KM, Mohile SG, Magnuson A, Kleckner IR, Guido JJ, Young KL, Conlin AK, Weiselberg LR, Mitchell JW, Ambrosone CA, Ahles TA, Morrow GR (2017) Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol 35(5):506–514CrossRefPubMedGoogle Scholar
- 34.Zer A, Pond GR, Razak ARA, Tirona K, Gan HK, Chen EX, O’Sullivan B, Waldron J, Goldstein DP, Weinreb I, Hope AJ, Kim JJ, Chan KKW, Chan AK, Siu LL, Bernstein LJ (2017) Association of neurocognitive deficits with radiotherapy or chemoradiotherapy for patients with head and neck cancer. JAMA Otolaryngol- Head Neck SurgGoogle Scholar
- 39.Day J, Zienius K, Gehring K, Grosshans D, Taphoorn M, Grant R et al Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation. Cochrane Database Syst Rev (2014, 12):CD011335Google Scholar
- 40.Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org.
- 41.Review Manager (RevMan) [Computer program] (2014) Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane CollaborationGoogle Scholar
- 44.Mar Fan HG, Clemons M, Xu W, Chemerynsky I, Breunis H, Braganza S, Tannock IF (2008) A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 16(6):577–583CrossRefPubMedGoogle Scholar
- 45.Escalante CP, Meyers C, Reuben JM, Wang X, Qiao W, Manzullo E, Alvarez RH, Morrow PK, Gonzalez-Angulo AM, Wang XS, Mendoza T, Liu W, Holmes H, Hwang J, Pisters K, Overman M, Cleeland C (2014) A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J 20(1):8–14CrossRefPubMedGoogle Scholar
- 46.Kohli S, Fisher SG, Tra Y, Adams MJ, Mapstone ME, Wesnes KA, et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer. 2009;115:2605-16.Google Scholar
- 47.Berenson JR, Yellin O, Shamasunder HK, Chen CS, Charu V, Woliver TB, Sanani S, Schlutz M, Nassir Y, Swift RA, Andreu-Vieyra C, Vescio R (2015) A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Support Care Cancer 23(6):1503–1512CrossRefPubMedGoogle Scholar
- 51.Berenson JR, Yellin O, Shamasunder HK, Chen CS, Charu V, Woliver TB, Sanani S, Schlutz M, Nassir Y, Swift RA, Andreu-Vieyra C, Vescio R (2015) A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Support Care Cancer 23(6):1503–1512CrossRefPubMedGoogle Scholar
- 52.Tao L, Lin H, Yan Y, Xu X, Wang L, Zhang J, Yu Y (2017) Impairment of the executive function in breast cancer patients receiving chemotherapy treatment: a functional MRI study. Eur J Cancer Care (Engl) 26(6)Google Scholar
- 60.Rapp SR, Case LD, Peiffer A, Naughton MM, Chan MD, Stieber VW, Moore DF Jr, Falchuk SC, Piephoff JV, Edenfield WJ, Giguere JK, Loghin ME, Shaw EG (2015) Donepezil for irradiated brain tumor survivors: a phase III randomized placebo-controlled clinical trial. J Clin Oncol : Off J Am Soc Clin Oncol 33(15):1653–1659CrossRefGoogle Scholar
- 75.Chung NC, Walker AK, Dhillon HM, Vardy JL (2018) Mechanisms and treatment for cancer- and chemotherapy-related cognitive impairment in survivors of non-CNS malignancies. Oncology (Williston Park, NY) 32(12):591–598Google Scholar
- 76.Hartman SJ, Nelson SH, Myers E, Natarajan L, Sears DD, Palmer BW, Weiner LS, Parker BA, Patterson RE (2018) Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: the memory & motion study. Cancer. 124(1):192–202CrossRefPubMedGoogle Scholar
- 78.Derry HM, Jaremka LM, Bennett JM, Peng J, Andridge R, Shapiro C, Malarkey WB, Emery CF, Layman R, Mrozek E, Glaser R, Kiecolt-Glaser JK (2015) Yoga and self-reported cognitive problems in breast cancer survivors: a randomized controlled trial. Psychooncology. 24(8):958–966CrossRefPubMedGoogle Scholar
- 79.Janelsins MC, Peppone LJ, Heckler CE, Kesler SR, Sprod LK, Atkins J, Melnik M, Kamen C, Giguere J, Messino MJ, Mohile SG, Mustian KM (2016) YOCAS(c)(R) yoga reduces self-reported memory difficulty in cancer survivors in a Nationwide randomized clinical trial: investigating relationships between memory and sleep. Integr Cancer Ther 15(3):263–271CrossRefPubMedGoogle Scholar